

Application/Control Number: 09/849,870

Page 2

Art Unit: 1600

CLMPTO

08/03/2004

DM

1. (Currently amended) A pharmaceutical composition adapted for delivery to a subject comprising:

a) an azide derivative of a drug, which drug comprises an amino or hydroxyl moiety, wherein in said azide derivative an azide group occurs at the site of said amino or hydroxyl moiety in place of said moiety, said azide derivative being capable of being converted to said drug in vivo by replacement of said azide group with said amino or hydroxyl moiety of said drug; and

b) a suitable pharmaceutical carrier,

wherein said drug is a biologically active therapeutic purine compound or a purine nucleoside or purine nucleotide compound and said azide group occurs on the 6-position of said purine compound or said purine nucleoside or nucleotide compound.

2-23. Cancelled.

24. Cancelled.


25. (New) The composition according to claim 1 wherein said drug is a purine compound.

26. (New) The composition according to claim 1 wherein said drug is a purine nucleoside or purine nucleotide compound.

27. (New) The composition according to claim 26 wherein said drug is a purine nucleoside compound.

28. (New) The composition according to claim 26 wherein said drug is a purine nucleotide compound.

29. (Currently amended) The composition according to claim 1 wherein said azide derivative has the formula



wherein  $R_1$  is

(1) a substituted or unsubstituted furanose or dioxolane that is bound at the 1' position to the N 9 ring nitrogen of the purine of formula (I), or is

(2)  $R_1-OR_4$ , where  $R_3$  is a  $C_1-C_5$  alkyl, alkenyl, or alkynyl and  $-OR_4$  is a  $C_2-C_5$  alkoxy carbonyl or alkoxy alcohol, and  
wherein  $R_2$  is H, OH, Cl,  $NH_2$ , or  $NHAc$ .

30. (New) The composition according to claim 29 wherein  $R_1$  is furanose,  $R^3$  is a  $C_2-C_5$  alkyl and  $-OR_4$  is a  $C_2-C_5$  alkoxy alcohol.

31. (New) The composition according to claim 29 wherein  $R_1$  is dioxolane.